Krishna Institute of Medical Sciences Limited (KIMS Hospitals) announced the outcome of its Board Meeting held on August 3, 2026. The Board reviewed and approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. Additionally, the company approved extending loans and guarantees up to ₹650 Crores and a specific loan of ₹25 Crores to a material subsidiary.
KIMS Hospitals Reports Q1 FY27 Financials, Approves Major Financial Actions
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has disclosed key outcomes from its Board Meeting convened on August 3, 2026. The Board meticulously reviewed, deliberated upon, and formally approved the unaudited standalone and consolidated financial results for the first quarter of the financial year ending June 30, 2026. These results, along with the Limited Review Reports, have been presented as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Significant Financial Approvals
In addition to the financial results, the Board of Directors greenlit several crucial financial proposals. They approved the advancement of loans, guarantees, or securities up to a cumulative limit of ₹650 Crores. This limit is in excess of the provisions under Section 186 of the Companies Act, 2013 and is subject to shareholder approval via a special resolution. Furthermore, a specific loan of up to ₹25 Crores has been approved for KIMS Hospital Enterprises Private Limited, a material subsidiary.
Strategic Agreements
The meeting also saw the consideration and approval of a DRAFT Operations & Management (O&M) agreement and a Call Option Agreement. These agreements are with Golden Lan Solutions Private Limited and Sarwottam Healthcare Private Limited. The company intends to provide further SEBI disclosures upon the execution of these definitive agreements.
Financial Information Availability
The audited financial results for the quarter are accessible on the company’s official website at https://www.kimshospitals.com/investors/Disclosures, adhering to Regulation 46 of the SEBI (LODR) Regulations, 2015. They are also available on the websites of the BSE (www.bseindia.com) and NSE (www.nseindia.com).
Financial Highlights (Unaudited Standalone Results – Quarter ended 30 June 2026)
- Revenue from operations: ₹4,836 million
- Other income: ₹307 million
- Total Income: ₹5,143 million
- Total Expenses: ₹4,255 million
- Profit before tax: ₹888 million
- Tax expense: ₹223 million
- Profit for the period: ₹665 million
- Total comprehensive income: ₹665 million
Financial Highlights (Unaudited Consolidated Results – Quarter ended 30 June 2026)
- Revenue from operations: ₹11,795 million
- Other income: ₹164 million
- Total Income: ₹11,959 million
- Total Expenses: ₹11,403 million
- Profit before share of profit from associate: ₹556 million
- Profit before tax: ₹566 million
- Tax expense: ₹192 million
- Profit for the period: ₹374 million
- Total comprehensive income: ₹374 million
Source: BSE
